|Awarded On||February 15, 2023|
|Title||The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T Cell Therapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Texas A&M University|
|Principal Investigator/Program Director||Wenshe Liu|
|Cancer Sites||Leukemia, Lymphoma, Myeloma|
*Pending contract negotiation
The development of chimeric antigen receptor (CAR) T cell therapeutics has revolutionized clinical intervention of cancer. Crowned as live drugs, CAR-T cell therapy has demonstrated success in the elimination of hematopoietic tumors including different types of leukemia, lymphoma and myeloma. Several CAR-T therapeutics have been clinically approved. Many others are on clinical trials. Although extremely powerful, CAR-T cell therapy suffers from serious safety concerns including cytokine release syndrome, neurological toxicity, tumor lysis syndrome, on-target/off-tumor toxicity, anaphylaxis, and hematological toxicity. Besides safety concerns, there are other challenges that limit efficacy of...